Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346)
- 1 October 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 188 (4) , 1164-1169
Abstract
Frequent prostate specific antigen testing for screening and monitoring prostate cancer has led to significant stage migration. We evaluated whether overall survival in hormone naïve patients with metastatic prostate cancer has improved during the era of prostate specific antigen use. We also assessed whether any patient subsets benefited differentially during this period. We compared overall survival in 3 sequential phase III trials of 3,096 men with hormone naïve, metastatic prostate cancer who received similar androgen deprivation therapy, including 2 trials performed before the prostate specific antigen era (S8494 and S8894) and the other done during this era (S9346). Overall survival was adjusted for patient and disease risk factors in the latter 2 trials. Subgroups were evaluated by interactions of risk factors with trial. Median overall survival was 30 months in S8494, 33 months in S8894 and 49 months in S9346. Adjusting for risk factors, there was a 22% lower risk of death in S9346 than in S8894 (HR 0.78, 95% CI 0.70, 0.87, p <0.001). The improvement in overall survival was greater in black American men (test of interaction p = 0.008). In S8494 and S8894 median survival for black men was 27 months, and 34 and 35 months for nonblack men, respectively. This racial difference disappeared in S9346 with overall survival of 48 and 49 months in black and nonblack men, respectively. Adjusting for risk factors, overall survival was significantly improved in the post-prostate specific antigen era trial. However, it cannot be concluded that this was attributable only to prostate specific antigen monitoring. Black men now have overall survival comparable to that of white men. Current estimates of survival should be used to design new trials in this population.Keywords
This publication has 15 references indexed in Scilit:
- Mortality Results from a Randomized Prostate-Cancer Screening TrialNew England Journal of Medicine, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling ApproachMedical Decision Making, 2008
- Prostate‐specific antigen velocity and survival for patients with hormone‐refractory metastatic prostate carcinomaCancer, 2005
- SURROGATE END POINT FOR PROSTATE CANCER SPECIFIC MORTALITY IN PATIENTS WITH NONMETASTATIC HORMONE REFRACTORY PROSTATE CANCERJournal of Urology, 2005
- The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary ManagementJournal of Clinical Oncology, 2004
- Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate CancerJournal of Clinical Oncology, 2003
- Prostate Cancer Stage Shift has Eliminated the Gap in Disease-free Survival in Black and White American Men after Radical ProstatectomyJournal of Urology, 2002
- Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate CancerNew England Journal of Medicine, 1998
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989